A dose‐finding study of once‐daily oral telbivudine in HBeAg‐positive patients with chronic hepatitis B virus infection

Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response rates, cumulative viral resistance, and/or poor tolerability. Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical sa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology (Baltimore, Md.) Md.), 2004-09, Vol.40 (3), p.719-726
Hauptverfasser:	Lai, Ching‐Lung, Lim, Seng Gee, Brown, Nathaniel A., Zhou, Xiao‐Jian, Lloyd, Deborah M., Lee, Yin‐Mei, Yuen, Man‐Fung, Chao, George C., Myers, Maureen W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences DNA, Viral - blood Dose-Response Relationship, Drug Drug Administration Schedule Female Hepatitis B e Antigens - analysis Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Human viral diseases Humans Infectious diseases Male Medical sciences Middle Aged Nucleosides - administration & dosage Nucleosides - adverse effects Nucleosides - pharmacokinetics Pharmacology. Drug treatments Pyrimidinones - administration & dosage Pyrimidinones - adverse effects Pyrimidinones - pharmacokinetics Thymidine - analogs & derivatives Viral diseases Viral diseases of the digestive system Viral hepatitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!